Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Brain Neoplasms 9Carcinoma, Non-Small-Cell Lung 3Recurrence 2Melanoma 2Glioblastoma 2Neuroblastoma 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Cognition Disorders 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 19Radiosurgery 16Radiotherapy 14Specimen Handling 11Pemetrexed 8Paclitaxel 6Erlotinib Hydrochloride 6Docetaxel 6Carboplatin 6Bevacizumab 5pembrolizumab 4Temozolomide 4Spinal Puncture 4Cisplatin 4osimertinib 3Taxes 3Nivolumab 3Gemcitabine 3Gefitinib 3Filgrastim 3Drug Therapy 3trametinib 2selpercatinib 2sapanisertib 2motexafin gadolinium 2epothilone B 2dabrafenib 2X-Rays 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Spermine Synthase × CNS × Clear all
NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡